Business Wire

Sentry Raises $90 Million in Series E Funding to Expand and Drive Adoption of Developer-first Application Monitoring

4.5.2022 16:00:00 EEST | Business Wire | Press release

Share

Sentry, the market leader in developer-first application monitoring, today announced it has raised $90 million for its Series E, bringing the company’s total funding to $217 million and valuing the company at more than $3 billion. This round was co-led by BOND and Accel, with participation from existing investor New Enterprise Associates (NEA) and new investor K5 Global. The new capital will help fuel the company’s long-term growth for product development, hiring, and global expansion in Europe.

Sentry is reshaping application performance monitoring (APM) by directly addressing the developer experience gap. With the proliferation of applications, languages, and frameworks, Sentry empowers any developer or development team to solve issues in production code by using one tool to monitor for errors, performance, and health across mobile, desktop, and IoT, and across any industry or vertical.

In the past year, the company saw rapid growth driven by customer adoption of Error and Performance Monitoring, with net expansion of annual recurring revenue (ARR) increasing by 130%+ year over year. Sentry now processes 790+ billion events per month, with mobile events increasing by more than 100% year over year.

“Our singular focus on developers, combined with the depth of our platform across 100+ languages, allows us to uniquely solve developer problems for every customer and software environment,” said Milin Desai, CEO at Sentry. “Revenue has more than tripled in just over two years, and our team will continue to be laser-focused on providing engineering organizations with the ability to ship better code faster.”

"Our customers expect constant improvements to the product experience along with new feature updates, and without any disruptions to their current workflows,” said Kah Seng Tay, GM and Head of Cloud and Developer Infrastructure at Airtable. “With Sentry providing accurate and diagnosable alerts, we’re able to better triage incidents during deployment and decentralize our release process. This all results in our engineering teams being able to ship code more efficiently and more frequently, while still keeping the quality of our service high."

“We ship a tremendous amount of code — eight deployments at the top of every hour — to launch new features. Combined with a highly distributed architecture, it was getting more and more complex for our teams to identify and fix errors and performance issues,” said Eviathar Moussaffi, Group Lead of Engineering at monday.com. “Providing the most optimal user experience to our customers is critical to the success of our business, and Sentry allows us to eliminate unnecessary noise and reduces the time to resolution, so our developers can be most effective. The demands on our business are only going to increase, and Sentry provides a way for our team to have a holistic view of the health of our applications.”

“The rate at which businesses are moving towards a digital-first mindset is unprecedented,” said Jay Simons, General Partner at BOND. “In order to sustain applications, programs, and mobile, the proper infrastructure needs to be in place to manage and monitor the health of every customer solution. For many businesses, an error in code or a performance issue in the final touchpoint with an end-user can mean the loss of a sale or customer.”

“The rate of software development is going to exponentially increase, and developers are seeking ways to quickly solve any issues that will affect the end-user experience,” said Dan Levine, Partner at Accel, a firm that has also invested in companies like Atlassian, CrowdStrike, Dropbox, PagerDuty, Qualtrics, and Slack. “With Sentry, companies can not only pinpoint the exact issue but also proactively monitor their application health. As we continue to see the move towards a digital-first world, Sentry is well-positioned to help companies, from small businesses to enterprises, ensure that they’re keeping up with customer expectations.”

To support growing demand, Sentry’s team has grown nearly 75% worldwide since this time last year, with plans to continue hiring for all offices, including a new hub opening in Europe. With this round of funding, Sentry will accelerate its go-to-market motion and teams, as the company expands on its product-led growth model and servicing its global customer base.

Learn more about Sentry’s plans for innovation and growth on the company blog.

About Sentry

For software teams, Sentry is essential for monitoring code health. From Error tracking to Performance Monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Peloton, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble or LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Janet Park
Sentry
media@sentry.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye